IRF7 Antikörper (AA 131-289)

Produktnummer ABIN7156631

Produktdetails anti-IRF7 Antikörper

Target: IRF7 (Interferon Regulatory Factor 7 (IRF7))

Bindungsspezifität: AA 131-289

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IRF7 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Interferon regulatory factor 7 protein (131-289AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu IRF7

Target: IRF7 (Interferon Regulatory Factor 7 (IRF7))

Andere Bezeichnung: IRF7 (IRF7 Produkte)

Synonyme: wu:fl24c03 antikoerper, zgc:66043 antikoerper, zgc:77947 antikoerper, IRF7 antikoerper, irf7 antikoerper, IRF-7H antikoerper, IRF7A antikoerper, IRF7B antikoerper, IRF7C antikoerper, IRF7H antikoerper, interferon regulatory factor 7 antikoerper, irf7 antikoerper, IRF7 antikoerper, Irf7 antikoerper

Hintergrund:

Background: Key transcriptional regulator of type I interferon (IFN)-dependent immune responses and plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Can efficiently activate both the IFN-beta (IFNB) and the IFN-alpha (IFNA) genes and mediate their induction via both the virus-activated, MyD88-independent pathway and the TLR-activated, MyD88-dependent pathway. Required during both the early and late phases of the IFN gene induction but is more critical for the late than for the early phase. Exists in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, becomes phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization where along with other coactivators it can activate transcription of the type I IFN and ISG genes. Can also play a role in regulating adaptive immune responses by inducing PSMB9/LMP2 expression, either directly or through induction of IRF1. Binds to the Q promoter (Qp) of EBV nuclear antigen 1 a (EBNA1) and may play a role in the regulation of EBV latency. Can activate distinct gene expression programs in macrophages and regulate the anti-tumor properties of primary macrophages.

Aliases: IMD39 antibody, Interferon regulatory factor 7 antibody, Interferon regulatory factor 7H antibody, IRF 7 antibody, IRF 7A antibody, IRF 7H antibody, IRF-7 antibody, IRF7 antibody, IRF7_HUMAN antibody, IRF7A antibody, IRF7B antibody, IRF7C antibody, IRF7H antibody

UniProt: Q92985

Pathways: TLR Signalweg, Activation of Innate immune Response, Hepatitis C, Toll-Like Receptors Cascades, Autophagie